MANE
Veradermics, IncorporatedHealthcare·Biotechnology
$100.91
$4.2B market cap
Revenue
$0.0M
Free Cash Flow
$-44.8M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA
2-Year Price History
$101.62+164.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -29.9 | -29.9 | -27.2 | -21.2 | -21.2 | -0.0 | 390.8 | 0.0 | 37.3 | -23.3% | -- | -- |
| Act | 2025-Q4 | 0.0 | -23.0 | -23.0 | -21.9 | -23.6 | -23.6 | -0.0 | 141.9 | 0.0 | 37.3 | <-999% | -43.3x | -- |
Valuation & Metrics
Market Stats
Price$100.91
Market Cap$4.2B
Enterprise Value$3.8B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-1.1%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-49.1M
Free Cash Flow$-44.8M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-1150561.6%
WC Change % Rev0.0%
Interest Coverage-99.4x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.1M
Days to Cover2.5
Change (vs Prior)+15.0%
Need at least 2 settlement dates for chart
Employees
Headcount21
Revenue / Employee$0
Gross Profit / Employee$0
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
35.9%
72 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
2.0%
8 filers
Vanguard, iShares, SPDR
Market makers
0.0%
1 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
Not enough quarterly ownership history to chart yet.
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | $263M | $63.15 | +$263M | +$263M | — | $3.69B |
| SR ONE CAPITAL MANAGEMENT, LP | $152M | $63.15 | +$152M | +$152M | — | $915M |
| CITADEL ADVISORS LLC | $115M | $63.15 | +$115M | +$115M | — | $138.22B |
| FMR LLC | $113M | $63.15 | +$113M | +$113M | — | $1.89T |
| VIKING GLOBAL INVESTORS LP | $107M | $63.15 | +$107M | +$107M | — | $35.75B |
| Siren, L.L.C. | $95.1M | $63.15 | +$95.1M | +$95.1M | — | $3.61B |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $69.5M | $63.15 | +$69.5M | +$69.5M | — | $64.61B |
| Aberdeen Group plc | $66.6M | $63.15 | +$66.6M | +$66.6M | — | $61.88B |
| JPMORGAN CHASE & CO | $59.4M | $63.15 | +$61.6M | +$59.4M | — | $1.47T |
| INFINITUM ASSET MANAGEMENT, LLC | $46.2M | $63.15 | +$46.2M | +$46.2M | — | $799M |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $44.2M | $63.15 | +$44.2M | +$44.2M | — | $4.04T |
| MARSHALL WACE, LLP | $41.3M | $63.15 | +$41.3M | +$41.3M | — | $92.71B |
| BALYASNY ASSET MANAGEMENT LLC | $33.7M | $63.15 | +$33.7M | +$33.7M | — | $48.01B |
| Paradigm Biocapital Advisors LP | $33.2M | $63.15 | +$33.2M | +$33.2M | — | $4.69B |
| AMERIPRISE FINANCIAL INC | $32.5M | $63.15 | +$32.5M | +$32.5M | — | $430.96B |
| Woodline Partners LP | $31.6M | $63.15 | +$31.6M | +$31.6M | — | $26.43B |
| Deep Track Capital, LP | $31.6M | $63.15 | +$31.6M | +$31.6M | — | $4.85B |
| WELLINGTON MANAGEMENT GROUP LLP | $30.2M | $63.15 | +$30.2M | +$30.2M | — | $533.98B |
| UBS Group AG | $21.9M | $63.15 | +$21.9M | +$21.9M | — | $562.11B |
| Vivo Capital, LLC | $18.9M | $63.15 | +$18.9M | +$18.9M | — | $1.20B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-2.00%
avg per quarter
Holders (ex-self)
—
excl. this stock
Buyers (this Q)
-2.00%
81 buyers · $1.64B in
Sellers (this Q)
+0.00%
0 sellers · $0.00B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-1.9%
how holders react when this stock falls
On quiet Qs
-3.1%
−10% to +10% baseline
On rallies (+10%+)
-8.3%
how they react when this stock rises
Holders' portfolio flow this Q
+4.3%
inflows — adds are organic
Sellers' portfolio flow this Q
+0.0%
Sellers' overall flow ~ flat.
New buyers this quarter
Top-5 holders · 45.8%
SUVRETTA CAPITAL MANAGEMENT, LLC--
SR ONE CAPITAL MANAGEMENT, LP--
CITADEL ADVISORS LLC--
FMR LLC--
VIKING GLOBAL INVESTORS LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
Not enough holder history to plot.
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$75.00-2570.0%
Last Year (1 analysts)$75.00-2570.0%
Current Price$100.91
Analyst Ratings
2
Buy: 2Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
14.3%retail+2.0pp
38.8%dark-0.9pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.